JPWO2020028857A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020028857A5
JPWO2020028857A5 JP2021529259A JP2021529259A JPWO2020028857A5 JP WO2020028857 A5 JPWO2020028857 A5 JP WO2020028857A5 JP 2021529259 A JP2021529259 A JP 2021529259A JP 2021529259 A JP2021529259 A JP 2021529259A JP WO2020028857 A5 JPWO2020028857 A5 JP WO2020028857A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
muscle
transferrin receptor
conjugate
receptor antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021529259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533198A (ja
JP7576542B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044982 external-priority patent/WO2020028857A1/en
Publication of JP2021533198A publication Critical patent/JP2021533198A/ja
Publication of JPWO2020028857A5 publication Critical patent/JPWO2020028857A5/ja
Priority to JP2024184975A priority Critical patent/JP7708957B2/ja
Application granted granted Critical
Publication of JP7576542B2 publication Critical patent/JP7576542B2/ja
Priority to JP2025112731A priority patent/JP2025175995A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529259A 2018-08-02 2019-08-02 筋標的化複合体およびそれらの使用 Active JP7576542B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024184975A JP7708957B2 (ja) 2018-08-02 2024-10-21 筋標的化複合体およびそれらの使用
JP2025112731A JP2025175995A (ja) 2018-08-02 2025-07-03 筋標的化複合体およびそれらの使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862714010P 2018-08-02 2018-08-02
US62/714,010 2018-08-02
US201862779173P 2018-12-13 2018-12-13
US62/779,173 2018-12-13
US201962855781P 2019-05-31 2019-05-31
US62/855,781 2019-05-31
US201962858925P 2019-06-07 2019-06-07
US62/858,925 2019-06-07
US201962859694P 2019-06-10 2019-06-10
US62/859,694 2019-06-10
PCT/US2019/044982 WO2020028857A1 (en) 2018-08-02 2019-08-02 Muscle-targeting complexes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024184975A Division JP7708957B2 (ja) 2018-08-02 2024-10-21 筋標的化複合体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021533198A JP2021533198A (ja) 2021-12-02
JPWO2020028857A5 true JPWO2020028857A5 (enExample) 2022-08-10
JP7576542B2 JP7576542B2 (ja) 2024-10-31

Family

ID=69232332

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021529259A Active JP7576542B2 (ja) 2018-08-02 2019-08-02 筋標的化複合体およびそれらの使用
JP2024184975A Active JP7708957B2 (ja) 2018-08-02 2024-10-21 筋標的化複合体およびそれらの使用
JP2025112731A Pending JP2025175995A (ja) 2018-08-02 2025-07-03 筋標的化複合体およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024184975A Active JP7708957B2 (ja) 2018-08-02 2024-10-21 筋標的化複合体およびそれらの使用
JP2025112731A Pending JP2025175995A (ja) 2018-08-02 2025-07-03 筋標的化複合体およびそれらの使用

Country Status (11)

Country Link
US (2) US20210261680A1 (enExample)
EP (1) EP3829649A4 (enExample)
JP (3) JP7576542B2 (enExample)
KR (1) KR20210086602A (enExample)
CN (1) CN112930197A (enExample)
AU (1) AU2019315593A1 (enExample)
CA (1) CA3108335A1 (enExample)
IL (3) IL320597A (enExample)
MX (1) MX2021001282A (enExample)
SG (1) SG11202100931QA (enExample)
WO (1) WO2020028857A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP7506601B2 (ja) * 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
WO2020028840A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating friedreich's ataxia
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
EP3829649A4 (en) * 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. ANTI-MUSCLE COMPLEXES AND THEIR USES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230144436A1 (en) * 2020-01-10 2023-05-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP4656242A2 (en) 2020-03-27 2025-12-03 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
WO2021226107A1 (en) * 2020-05-05 2021-11-11 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
US20230201358A1 (en) * 2020-05-08 2023-06-29 Mpeg La, L.L.C. Linker compounds
MX2023000958A (es) * 2020-07-23 2023-04-14 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica.
CA3186755A1 (en) * 2020-07-23 2022-01-27 Romesh R. Subramanian Muscle-targeting complexes and uses thereof
WO2022120132A1 (en) * 2020-12-04 2022-06-09 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
EP4271816A4 (en) * 2020-12-31 2025-04-02 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
WO2022197554A1 (en) * 2021-03-16 2022-09-22 University Of Massachusetts Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
MX2024000489A (es) 2021-07-09 2024-04-09 Dyne Therapeutics Inc Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías.
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
KR20240107202A (ko) 2021-09-01 2024-07-08 바이오젠 엠에이 인코포레이티드 항-트랜스페린 수용체 항체 및 이의 용도
MX2024003753A (es) * 2021-09-29 2024-04-16 Ionis Pharmaceuticals Inc Oligonucleotidos conjugados y usos de estos.
EP4452281A1 (en) 2021-12-22 2024-10-30 Sapreme Technologies B.V. Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
IL313728A (en) 2021-12-22 2024-08-01 Sapreme Tech Bv Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
CN118434449A (zh) 2021-12-22 2024-08-02 萨普雷米科技有限公司 包含用于治疗肌肉消耗障碍的治疗性核酸和靶向皂苷的组合物
EP4460333A2 (en) * 2022-01-07 2024-11-13 Mirecule, Inc. Tissue-specific imaging and therapeutic agents targeting proteins expressed on muscle cell surface
CA3255934A1 (en) 2022-04-15 2023-10-19 Dyne Therapeutics, Inc. MUSCLE TARGETTING COMPLEXES AND FORMULATIONS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
US20240182561A1 (en) * 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
EP4480964A1 (en) * 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
AU2024314571A1 (en) * 2023-06-22 2025-12-18 Centre National De La Recherche Scientifique Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20120122801A1 (en) * 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
DK3252068T3 (da) * 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
WO2012178173A1 (en) * 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
CN105142672B (zh) * 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CA2897018C (en) * 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins
GB201507926D0 (en) * 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides
JP6823269B2 (ja) * 2016-06-20 2021-02-03 株式会社ＧｅｎＡｈｅａｄ Ｂｉｏ 抗体−薬物コンジュゲート
KR20190104381A (ko) * 2017-01-06 2019-09-09 어비디티 바이오사이언시스 엘엘씨 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
EP3829649A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. ANTI-MUSCLE COMPLEXES AND THEIR USES

Similar Documents

Publication Publication Date Title
JPWO2020028857A5 (enExample)
JP2025067909A5 (enExample)
JPWO2020028864A5 (enExample)
JPWO2020028861A5 (enExample)
JP7748962B2 (ja) 筋ジストロフィーを処置するための組成物および方法
EP2451480B1 (en) A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
JPWO2020028841A5 (enExample)
CN112912399A (zh) 肌肉靶向复合物及其用于治疗蓬佩病的用途
CN112955154A (zh) 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
CN112955153A (zh) 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
CN112930193A (zh) 肌肉靶向复合物及其在治疗肌肉萎缩中的用途
JPWO2020028840A5 (enExample)
CN118355035A (zh) 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
CN113166240A (zh) 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
CN118401553A (zh) 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
CN118251238A (zh) 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
JPWO2020028832A5 (enExample)
US9441221B2 (en) Compositions and methods for gene silencing
JPWO2022020107A5 (enExample)
JPWO2022020108A5 (enExample)
JPWO2021142227A5 (enExample)
JPWO2021142275A5 (enExample)
JPWO2022020106A5 (enExample)
JPWO2022026152A5 (enExample)
AU2003213047A1 (en) Protein carrier system for therapeutic oligonucleotides